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Abstract
The potential use of clinically approved beta-lactams for Buruli ulcer (BU) treatment was
investigated with representative classes analyzed in vitro for activity againstMycobacterium
ulcerans. Beta-lactams tested were effective alone and displayed a strong synergistic profile
in combination with antibiotics currently used to treat BU, i.e. rifampicin and clarithromycin;
this activity was further potentiated in the presence of the beta-lactamase inhibitor clavula-
nate. In addition, quadruple combinations of rifampicin, clarithromycin, clavulanate and
beta-lactams resulted in multiplicative reductions in their minimal inhibitory concentration
(MIC) values. The MIC of amoxicillin against a panel of clinical isolates decreasedmore
than 200-fold within this quadruple combination. Amoxicillin/clavulanate formulations are
readily available with clinical pedigree, low toxicity, and orally and pediatric available; thus,
supporting its potential inclusion as a new anti-BU drug in current combination therapies.
Author summary
Buruli ulcer (BU) is a chronic debilitating disease of the skin and soft tissue, mainly affect-
ing children and young adults in tropical regions. Before 2004, the only treatment option
was surgery; a major breakthrough was the discovery that BU could be cured in most
cases with a standard treatment that involved 8 weeks of combination therapy with rifam-
picin and streptomycin. However, the use of streptomycin is often associated with severe
side effects such as ototoxicity, or nephrotoxicity. More recently, a clinical trial demon-
strated equipotency of replacing the injectable streptomycin by the clarithromycin, which
is orally available and associated with fewer side effects. BU treatment is now moving
toward a full orally available treatment of clarithromycin-rifampicin. Although effective
and mostly well tolerated, this new treatment is still associated with side effects and only
moxifloxacin is additionally recommended by WHO for BU therapy. New drugs are thus
needed to increase the number of available treatments, reduce side effects, and improve
efficacy with treatments shorter than 8 weeks. In this work, we describe for the first time
the potential inclusion of beta-lactams in BU therapy. More specifically, we propose the
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use of amoxicillin/clavulanate since it is oral, suitable for the treatment of children, and
readily available with a long track record of clinical pedigree. Its inclusion in a triple oral
therapy complementing current combinatorial rifampicin-clarithromycin treatment has
the potential to counteract resistance development and to reduce length of treatment and
time to cure.
Introduction
Buruli ulcer (BU) is a chronic debilitating mycobacterial disease of the skin and soft tissue.
Although mortality is low, permanent disfigurement and disability are high, mainly affecting
children and young adults. BU is found primarily in tropical regions of Africa, South America
and the Western Pacific; however, it is also becoming a public health concern in some regions
of Australia [1].
Before 2004, when the World Health Organization (WHO) published provisional guidance
for the management of BU disease [2], antibiotics were viewed as relatively ineffective and sur-
gery remained the mainstay of treatment for BU [3–5]. In the late 1990s and early 2000s, how-
ever, in vitro studies demonstrated anti-BU activity of some antibiotics used for the treatment
of tuberculosis (TB) and other non-tuberculous mycobacteria [6–8], and in vivo studies the
potential for combining two drugs to provide improved treatment outcomes [9–13]. Soon
after, clinical evidence showed the effectiveness of a combination of rifampicin plus streptomy-
cin when it was administered for at least 4 weeks [14], and that routine implementation of
such a therapy was possible in the field [15, 16]; however, the use of the injectable streptomycin
is often associated with adverse events and it is restricted in the treatment of pregnant women
and young infants. In addition, the lack of an efficacious oral treatment remained one of the
main obstacles to decentralizing care at local level in rural areas. These limitations motivated
the scientific community to evaluate alternative oral treatments and clinical studies demon-
strated that fluoroquinolones [17] or clarithromycin [18–20] could also be used in combina-
tion with rifampicin and were associated with fewer side effects compared to the injectable
streptomycin. Thus, on March 24th, 2017, WHO recommended full oral treatment of 8 weeks
daily combination therapy of rifampicin-clarithromycin [21].
While recommended regimens (rifampicin plus streptomycin or clarithromycin) allow
cure of small lesions (<5 cm in diameter) without surgery [15, 18], controversy remains
regarding the best surgery approach for large lesions (>10 cm) [22, 23]. Intermittent drug
administration using rifapentine, a rifampicin analog with longer half-life, instead of daily
rifampicin, has been also proposed as a strategy to facilitate treatment supervision in the field
[24]. However, M. ulcerans strains resistant to rifampicin have been isolated after experimental
chemotherapy in mice [25] and a recent report described the emergence of M. ulcerans strains
resistant to rifampicin and streptomycin in the clinic [26]; further experiments would be, how-
ever, needed to identify the genetic basis of such resistance patterns and confirm the emer-
gence of resistance in M. ulcerans clinical isolates. Nevertheless, these reports should be a
warning sign since no alternatives for rifampicin are currently available. WHO currently rec-
ommends only four drugs for the treatment of BU: rifampicin, streptomycin, clarithromycin
and moxifloxacin [2]. It would be thus desirable to increase the number of drugs available to
treat BU and to develop a new therapy that would reduce both duration of treatment and time
to healing after therapy completion for all type of lesions and suitable for children and preg-
nant women.
Beta-lactams for BU therapy
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Drug discovery and development for neglected diseases is especially delayed due to lack of
interest from the main scientific and industrial communities. To speed up the process in the
BU field, we applied knowledge gathered in TB R&D drug repurposing programs [27–30]
where we (and others [31]) showed that beta-lactams strongly increased the bactericidal and
sterilizing properties of rifampicin [28]. Rifampin is the cornerstone drug for TB (and BU)
therapy with a direct relation between dose increase and therapy efficacy [32] due to its bacte-
ricidal and sterilizing activity in a dose-dependent manner [33]. However, the current WHO
recommended 10 mg/kg (600 mg daily) is not its optimal clinical dosage [34] and some recent
studies suggest that it could be safely increased to 35 mg/kg daily for TB therapy with a bacteri-
ological effect on time to culture conversion [32, 35, 36]. More recently, dose-ranging high-
dose rifampicin studies using a murine model of M. ulcerans disease showed that shorter BU
treatments might be also feasible [37], suggesting that synergistic partners could serve to
improve rifampicin efficacy without compromising tolerability and toxicity.
Beta-lactams are one of the largest groups of antibiotics available today with an exceptional
record of clinical safety in humans [38]. Used for decades, they had been traditionally consid-
ered ineffective for the treatment of mycobacterial infections (mainly TB) due to the presence
of a beta-lactamase (BlaC) and the hydrophobic nature of the mycobacterial cell envelope [39].
However, after a seminal publication describing the in vitro activity of meropenem plus clavu-
lanate against multi-drug (MDR) and extensively drug resistant (XDR) strains of M. tuberculo-
sis [40] and its anecdotal use in salvage therapies for XDR patients [41], the first study
convincingly demonstrating the clinical efficacy of beta-lactams was recently published [29].
These studies provided evidence of their anti-mycobacterial clinical potential, opening a new
avenue to identify new drugs and optimize current BU therapy.
In this study, we are translating knowledge and concepts of drug repurposing and synergy
generated in TB R&D programs to assess the potential inclusion of beta-lactams for BU ther-
apy. We propose the combination of amoxicillin/clavulanate as a new anti-BU treatment in
combination with current oral BU therapy, rifampicin and clarithromycin, with the potential
of treatment shortening and readily implementation in the field.
Materials andmethods
Bacterial strains, growth conditions and reagents
M. ulcerans strain NCTC 10417 (ATCC Number: 19423; Lot Number: 63210551) was used for
initial screening assays. Further validation studies were performed with clinical isolates from
different geographical origins: ITM 063846, Benin; ITM 070290, China; ITM 083720 and ITM
C05143, Mexico; ITM 941327, ITM C05142 and ITM M000932, Australia; ITM C05150, DR
Congo; ITM C08756, Japan, purchased from the Belgian Co-ordinated Collection of Micro-
organisms (BCCM).
M. ulcerans cells were initially grown at 30˚C to an optical density at 600 nm (OD600) of
0.5–1.0 in tissue culture flasks containing 7H9 broth supplemented with 0.2% glycerol, 10%
OADC and 0.05% (vol/vol) Tyloxapol. Aliquots of 500 μL were then stored at -80˚C and the
number of colony forming units (CFU) in the freeze stock enumerated. Every experiment was
performed starting from a new frozen stock to avoid excessive passage of the original strain.
Cells were also routinely passaged on Middlebrook 7H10 agar plates (Difco) supplemented
with 10% (vol/vol) OADC to ensure purity of the isolate.
Rifampicin (R3501-1G; Lot Number: SLBH7862V) and meropenem (M2574; Lot Number:
055M4705V) were purchased from Sigma. GlaxoSmithKline provided clarithromycin, strepto-
mycin, clavulanate and all other beta-lactams used in this study.
Beta-lactams for BU therapy
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Drug susceptibility assays
Minimal Inhibitory Concentrations (MIC) were determined in 7H9 broth supplemented with
0.2% glycerol, 10% OADC and without Tyloxapol using triplicate two-fold serial dilutions of
compounds in polystyrene 384- or 96-well plates. MTT [3- (4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide] was used as the bacterial growth indicator [30, 42]. For cell
density calculations, a culture having an OD600 of 0.125 was found to contain approximately
107 cfu/mL. Cultures were sampled (50 μL in 384-well plates or 200 μL in 96-well plates) at a
final cell density of 106 cfu/mL and incubated at 30˚C in the presence of the drug (or drug
combinations) for 6 days before addition of 12.5 μL (384-well plates) or 30 μL (96-well plates)
of a MTT / Tween 80 (5 mg/mL / 20%) solution mix. After further overnight incubation at
37˚C, OD580 was measured. The lowest concentration of drug that inhibited 90% of the MTT
color conversion (IC90) was used to define MIC values.
Synergy assays
Checkerboard assays and calculations of the Fractional Inhibitory Concentration Index (FICI)
were used to define the degree of pairwise drug interactions, as previously described [28] (for a
visual representation and deeper understanding of the checkerboard assay refer to the supple-
mentary information of Ramo´n-Garcı´a et al.[30]). Up to quadruple combinations of rifampi-
cin, clarithromycin, beta-lactams and clavulanate were also tested. For this, checkerboard
plates were prepared with rifampicin in the y-axes, the beta-lactam in the x-axes, and clarithro-
mycin added in the z-axes as fixed sub-MIC (1/2, 1/4, and 1/8xMIC values) concentrations for
every checkerboard plate; typically the 1/8xMIC plate was used for synergy calculations of the
quad combos. When assayed, clavulanate was added at a fixed sub-MIC concentration of 5 μg/
mL. Increase efficacy of compounds (synergistic MIC, MICsyn) when in combination (fold-
MIC reduction) was always reported versus the activity of drugs alone. The Most Optimal
Combinatorial Concentration (MOCC) was defined as the lowest possible concentration of
every compound that, when assayed together, prevented bacterial growth, i.e. in an isobolo-
gram representation this would be the closest point to the axes intersection.
Results
Rifampicin has strong synergistic interactions with beta-lactams but not
with current anti-BU drugs
Clinically approved beta-lactams representing different sub-families, i.e. meropenem (carbape-
nems), cephradine and cefdinir (cephems), faropenem (penems) and amoxicillin (penicillins)
were assayed in vitro in a checkerboard format to assess their synergistic interactions with
rifampicin in the absence and presence of clavulanate, a beta-lactamase inhibitor, against the
M. ulcerans ATCC strain. A pattern of strong synergistic interaction was observed between
rifampicin and all beta-lactams tested (Fig 1); however, no interaction was observed when the
same assay was conducted using combinations of rifampicin and the currently WHO recom-
mended anti-BU drugs, i.e. streptomycin, clarithromycin and moxifloxacin (Fig 1 and S1 Fig).
Dose-response curves indicated that the activity of rifampicin (reflected in MIC reduction)
was increased on average 16-32-fold (up to 128-fold in some cases) and, vice versa, the activity
of the beta-lactams was strongly enhanced by rifampicin. In the case of amoxicillin, its activity
was further increased 512-fold in combination with clavulanate (S2 Fig and S1 Table).
Beta-lactams not only had synergistic interactions with rifampicin but also with clarithro-
mycin, the second drug recommended as first-line anti-BU therapy. These results prompted
us to test the inhibitory effect of double clarithromycin-beta lactam, and triple rifampicin-
Beta-lactams for BU therapy
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clarithromycin-beta-lactam combinations (Fig 2). Our results indicated that, when in double
or triple combinations, much lower sub-inhibitory concentrations were equally potent at
inhibiting M. ulcerans growth than the additive effects of the compounds alone. MIC values
were also lower than in other pairwise combinations. For example, the MIC of amoxicillin was
greater than 32 μg/mL; however, its synergistic MIC (MICsyn) was reduced to 1 μg/mL in the
presence of rifampicin, to 0.25 μg/mL when clavulanate was also added, or to 0.062 μg/mL
when both clavulanate and clarithromycin were included together with rifampicin, i.e., an
MIC reduction of ca. 500-fold for amoxicillin when in the quadruple combination. Similar
results were obtained for combinations of meropenem or faropenem and rifampicin, with
MIC reductions as high as 80-fold when tested within triple combinations. In these assays,
clarithromycin was added at a fixed concentration of 1/8 its MIC value alone, being its pres-
ence critical to achieve the multiplicative effect observe in the quadruple combinations.
STR vs. RIF AMK vs. RIF
CLA vs. RIF MOX vs. RIF
Current anti-BU drugs
CPD vs. RIF CPD vs. RIF
+CLV
CDN vs. RIF CDN vs. RIF
+CLV
Cephalosporins
AMX vs. RIF AMX vs. RIF
+CLV
FAR vs. RIF FAR vs. RIF
+CLV
MER vs. RIF MER vs. RIF
+CLV
Penem
Carbapenem
Penicillin
Fig 1. Synergistic profiles of current anti-BU drugs and selected beta-lactams with rifampicin against M. ulcerans
ATCC 19423. Compounds were assayed in two-fold serial dilutions in a checkerboard format. Rifampicin was assayed
in the x-axis while other drugs were assayed in the y-axis. RIF, rifampicin; STR, streptomycin; AMK, amikacin; CLA,
clarithromycin; MOX, moxifloxacin; CPD, cephradine; CDN, cefdinir; AMX, amoxicillin; FAR, faropenem; MER,
meropenem; CLV, clavulanate.
https://doi.org/10.1371/journal.pntd.0007126.g001
Beta-lactams for BU therapy
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Amoxicillin/clavulanate is highly active against M. ulcerans clinical isolates
in combination with rifampicin and clarithromycin
Our initial discoveries described above were performed using M. ulcerans ATCC 19423, a ref-
erence strain that does not produce mycolactone, a polyketide-derived macrolide secreted by
M. ulcerans and responsible for the tissue damage pathology in Buruli ulcer [43]. In order to
validate the pattern of synergistic interactions between rifampicin, clarithromycin and beta-
lactams and to gauge the potential of introducing a beta-lactam in the treatment of BU, we
expanded our analysis to a collection of M. ulcerans clinical isolates from different geographi-
cal locations and focused our synergy interaction studies on the amoxicillin /clavulanate com-
bination. When in the quadruple combinations, the activities of all three drugs (clavulanate
was added at a fixed 5 μg/mL concentration, more than 20-fold less its MIC) were strongly
Fig 2. Multiplicative effects of quadruple synergistic combinations including rifampicin, clarithromycin, clavulanate and different beta-lactams against M.
ulcerans ATCC 19423. The MIC of each compound was compared alone and in the presence of several synergistic combinations at the MOCC (lowest FICI).
Clarithromycin is not displayed since it was tested at a fixed 1/8xMIC concentration (MICCLA = 0.5 μg/mL). Clavulanate was tested at a fixed 5 μg/mL concentration.
AMX, amoxicillin; CLA, clarithromycin; CLV, clavulanate; FAR, faropenem; MER, meropenem; RIF, rifampicin.
https://doi.org/10.1371/journal.pntd.0007126.g002
Beta-lactams for BU therapy
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enhanced; depending on the strain tested, these interactions could range from ca. 5 to 600-fold
(rifampicin), ca. 4 to 2,000-fold (amoxicillin) and ca. 20 to 80-fold (clarithromycin) (Table 1).
Every possible pair-wise and triple combination was also evaluated showing strong synergism
between amoxicillin and both rifampicin and clarithromycin, but not between rifampicin and
clarithromycin, similar to previously described for the ATCC strain. Clavulanate enhanced the
activity of amoxicillin (as expected) but had no effect over clarithromycin and only minor
enhancements (in some cases) over rifampicin (S3 Table).
Amoxicillin is inactivated by beta-lactamase enzymes, limiting its clinical use. In fact, dose-
response studies demonstrated that amoxicillin alone was not active (MIC > 16 μg/mL); how-
ever, a strong shift in the dose-response curve was observed by adding clavulanate and this
shift was further enhanced when clarithromycin and rifampicin were also present in the com-
bination at sub-MIC concentrations (Fig 3), thus confirming our MIC/synergy data and the
potential of amoxicillin/clavulanate as a new anti-BU therapy, both alone and in combo with
rifampicin, clarithromycin or both.
Discussion
We have in vitro characterized the antimicrobial interactions of rifampicin with anti-BU drugs
and beta-lactams and found that, while there was no synergy between rifampicin and current
anti-BU drugs, it had strong synergistic interactions with beta-lactams. What is more, beta-lac-
tams also displayed synergism with clarithromycin, the other first line drug in BU therapy.
Our studies confirmed previous data showing lack of in vitro interaction between rifampicin
and clarithromycin [44], thus reinforcing synergy data observed with beta-lactams. Similar
observations of no interaction between rifampicin and clarithromycin were also recently
described in murine models of M. ulcerans infection [37]
Working with M. ulcerans is challenging due to its slow generation time (ca. 48 hours),
even slower than M. tuberculosis. Current methodologies to perform susceptibility testing
against clinical isolates are often time consuming and cumbersome (use of agar proportion
methods), thus, requiring several months to generate results [6, 8, 26]. Improvements have
been introduced using luminescent reporter strains [45]; however, this technology is limited to
specific engineered strains and cannot be widespread applied to clinical isolates. Here, we were
able to perform synergy studies, obtaining results in just seven days, in a medium-throughput
manner against a panel of clinical isolates by adapting a methodology previously described for
Table 1. Quadruple synergistic combinations among rifampicin, clarithromycin, amoxicillin and clavulanate against M. ulcerans clinical isolates.
MIC (μg/mL) alone MICsyn (μg/mL) at the MOCC Fold-Reduction at the MOCC
Clinical isolate Geographical origin RIF AMX CLA RIF AMX CLA RIF AMX CLA Quad FICI
ITM 063846 Benin 0.025 >32 0.125 0.0031 1 0.003 8 64 40 0.20
ITM 070290 China 0.5 >32 1 0.0016 0.063 0.05 313 1024 20 0.09
ITM 83720 Mexico 0.1 16 0.125 0.0063 0.063 0.003 16 256 40 0.13
ITM 941327 Australia 0.002 >32 0.5 0.0004 0.031 0.025 5 2065 20 0.29
ITM C05142 Australia 0.1 16 0.125 0.0016 0.063 0.0031 64 256 40 0.08
ITM C05143 Mexico 0.05 16 0.25 0.0008 4 0.0031 64 4 80 0.32
ITM C05150 DR Congo 0.02 >32 0.25 0.0013 0.063 0.0031 16 1024 80 0.12
ITM C08756 Japan 0.2 >32 0.25 0.0016 0.250 0.0125 128 256 20 0.10
ITM M000932 Australia 0.05 >32 0.063 0.0001 0.125 0.0031 640 256 20 0.09
Clavulanate was added to the quadruple combination at a fixed dose of 5 μg/mL. For FICI calculations, its MIC was considered as 128 μg/mL. RIF, rifampicin; AMX,
amoxicillin; CLA, clarithromycin; MOCC, Most Optimal Combinatorial Concentration; Fold-Reduction, MIC/MICsyn; FICI�0.5 indicates synergy.
https://doi.org/10.1371/journal.pntd.0007126.t001
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TB research and already validated to determine MIC values in slow growing mycobacteria
[28]. Similar redox-based assays (using alamar blue) have been previously employed in antimi-
crobial discovery programs targeting M. ulcerans [46, 47]. This methodology could provide a
cost and time effective assay to implement in the clinical practice in Buruli ulcer drug resis-
tance surveillance campaigns.
Over the last decade, BU therapy has undergone a tremendous improvement with the intro-
duction of chemotherapy; however, there is only a limited number of drugs recommended by
WHO for BU therapy, namely rifampicin, streptomycin, clarithromycin and moxifloxacin [2].
Current WHO recommended therapy is a fully oral eight weeks daily regimen with a combina-
tion of rifampicin and clarithromycin [20]. Although effective and mostly well tolerated, com-
bination treatment of rifampicin plus streptomycin or clarithromycin is associated with
undesirable side effects that might include mild (anorexia, nausea, abdominal pains and
altered taste) or severe (deafness, skin rashes, jaundice, shock, purpura or acute renal failure)
symptoms [2]. In a scenario where administration of any of these drugs needs to be inter-
rupted, therapeutic options would remain limited to the use of moxifloxacin, an antibiotic
contraindicated during pregnancy and within the pediatric population. A similar situation
Fig 3. Dose response curves of amoxicillin alone and in combination against M. ulcerans clinical isolates. Dose response curves of amoxicillin tested:
"alone", alone; "Plus CLV", in the presence of clavulanate; "at MOCC plus CLV", in the presence of clavulanate and rifampicin at the MOCC; "at MOCC
plus CLV/CLA", in the presence of clavulanate and rifampicin and clarithromycin at the MOCC. Clavulanate was tested at a fixed 5 μg/mL concentration.
AMX, amoxicillin; CLA, clarithromycin; CLV, clavulanate.
https://doi.org/10.1371/journal.pntd.0007126.g003
Beta-lactams for BU therapy
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would occur in the eventual development of resistance to any of these drugs, especially rifam-
picin. Since they are administered in pairwise combinations, this would effectively imply
monotherapy, further promoting the emergence of resistance. This is similar to another myco-
bacterial disease, leprosy, for which this threat was largely ignored and just recently WHO
issued guidelines including procedures for the detection of drug resistance [48]. Thus, an alter-
native drug regimen would be required to treat resistant M. ulcerans strains [26], even though
the emergence of resistance in M. ulcerans might follow different dynamics compared to M.
tuberculosis and M. leprae (environment vs. host reservoirs, respectively) and clinical resistance
has not been conclusively demonstrated to date.
BU is a neglected disease mainly affecting rural areas in under-resourced countries where
medicine access and logistics might prove difficult, and hospitalization and loss of income for
patients and families might compromise patient’s adherence to the 8-weeks antibiotic course.
A shortened, highly effective, all-oral regimen is urgently needed to improve care for this
neglected tropical disease; this would reduce indirect costs and barriers to therapy. The history
of TB chemotherapy teaches us that combination therapy is critical for optimal cure outcome
and treatment shortening [49]. Translation of this knowledge into BU therapy suggests that
more drugs need to be added to the current rifampicin-clarithromycin combination in order
to improve and shorten the duration of treatment.
Most beta-lactams tested in this study were active against M. ulcerans and enhanced the
anti-BU activity of rifampicin to different degrees. Cephradine is a first-generation cephalo-
sporins developed in the 1960s, also recently described to be active in vitro against M. tubercu-
losis [28]; however, cephradine was long ago discontinued and access to other first-generation
cephalosporins, such as cefadroxil or cephalexin, is limited in many countries. Cefdinir is a
third-generation cephalosporin active against pneumonia, skin and soft tissue infections,
although with low oral absorption [50]. It is currently used in the clinic, widely distributed and
access to it could be readily available; however, its synergistic profile with rifampicin was
weaker compared to other beta-lactams (S1 Table). Although meropenem was active against
pulmonary TB in a recent clinical study [29], it needs to be administered intravenously, not a
practical approach in under-resourced countries where oral drugs are required. Faropenem,
an orally administered beta-lactam, did not show activity in the same clinical trial due to the
low drug exposure in plasma after oral administration [29]. Finally, amoxicillin/clavulanate
showed good activity and very strong synergistic interaction with rifampicin.
The combination of amoxicillin plus clavulanate is a broad-spectrum antibacterial available
for clinical use in a wide range of indications and is now used primarily in the treatment of
community-acquired respiratory tract infections [51]. It was first launched in the UK in 1981;
by the end of 2002, it was clinically available in various formulations in over 150 countries
around the world. In addition to high efficacy, it has a well-known safety and tolerance profile,
including for pregnancy and pediatric used, based on over 819 million patient courses world-
wide, with the main contraindication being allergy to penicillin derivatives. Disruption of the
gut microbiota is the main side effect of long-term use of amoxicillin/clavulanate, mainly
caused by the presence of clavulanic acid in the formulation [52]. For TB treatment, amoxicil-
lin/clavulanate is included in Group 5 (anti-TB drugs with limited data on efficacy and long-
term safety in the treatment of drug-resistant TB) of the WHO 2011 TB drugs classification
and in Group D3 (add-on agents, not core MDR-TB regimen components) of the WHO 2016
MDR-TB drugs classification [53]. In 1983, Cynamon et al. reported the in vitro bactericidal
activity of amoxicillin/clavulanate against 15 isolates of M. tuberculosis, at concentrations of
amoxicillin lower than 4 μg/mL [54], and some years later, Nadler et al. case reported the effec-
tive treatment of MDR-TB patients with the addition of amoxicillin/clavulanate to the second-
line therapy [55]. Two contradictory follow up clinical studies, 2-days Early Bactericidal
Beta-lactams for BU therapy
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Activity (EBA), suggested that its activity was comparable to that reported for anti-TB agents,
other than isoniazid [56], but also questioned its role in the treatment of tuberculosis [57]. The
dosing interval of the amoxicillin/clavulanate therapy might explain these differences; while in
the first EBA it was divided into three daily doses, it was given as a single high dose in the sec-
ond one. More recently, a 14-days EBA study demonstrated activity of a combination of mero-
penem plus amoxicillin/clavulanate [29]; it remains to be determined whether this activity was
due to any of the components alone or the combination therapy as a whole [58]. In fact, in
vitro studies have demonstrated synergistic interactions among amoxicillin and meropenem
(and other beta-lactams), rifampicin and ethambutol against M. tuberculosis [28, 58–60].
In our in vitro assays with M. ulcerans clinical isolates, we found that amoxicillin had no
activity (typically MIC values > 16 μg/mL) but that its MIC could be reduced to 1 μg/mL in
the presence of clavulanate (S3 Table), similar to previously reported to the closely related M.
marinum species and other non-tuberculosis mycobacteria [61]. It also displayed strong syner-
gistic interactions with rifampicin and clarithromycin and, in quadruple combinations, its
activity was enhanced up to 2,000-fold in some cases, with average MIC ranges between 0.031
to 0.25 μg/mL (Table 1). For infections caused by other bacterial pathogens, susceptibility
breakpoints of amoxicillin/clavulanate are established at� 2 μg/mL (or� 4 μg/mL for high-
dose formulations) and mean peak plasma concentrations of amoxicillin range from 7.2 to
17 μg/mL, depending on the formulation [52], well above the synergistic MIC values reported
in this work. The bacteriological efficacy of penicillins is dependent on the time its free plasma
concentration remains above the MIC (time over the MIC value, fT>MIC). For other bacterial
infections, it has been estimated that a fT>MIC of ca. 30–40% of the dosing interval is required
for bactericidal activity [62]. In the case of M. ulcerans, this target therapy could be achieved
using standard amoxicillin/clavulanate formulations of 500/125 mg (4:1) or 875/125 mg (7:1)
administered three times a day, or the high-dose extended release formulation of 2000/125
(16:1) that would allow administration twice a day [52], an important consideration for treat-
ment compliance in under-resourced settings. Thus, according to our in vitro data, amoxicil-
lin/clavulanate could have an important role in the treatment of BU alone and, more
importantly, in combination with current first-line anti-BU therapy since no pharmacological
drug-drug interactions are described among amoxicillin/clavulanate and rifampicin or clari-
thromycin [51].
But, what could be the benefit of adding amoxicillin/clavulanate to the current anti-BU
therapy? Besides being able to treat secondary infections associated with BU lesions, it has
been proposed that the median time to healing is related to the bacterial load in the lesions at
the beginning of therapy and the presence of persister bacteria [63]; in fact, healing of up to
two thirds of patients occurs within 25 weeks from the start of treatment but for some patients
this can take up to a year. One of the reasons for this slow healing could be due to a high initial
bacterial load. In fact, active infection late into the recommended 8-week course of antibiotic
therapy could be found in slowly healing lesions [22, 64]. Extensive histopathologic studies
also demonstrated that M. ulcerans is essentially confined in extracellular areas of necrosis in
skin [6]. Under this circumstances, amoxicillin/clavulanate would be extremely effective at tar-
geting extracellular bacteria with rapid bactericidal activity, thus reducing initial bacterial bur-
den, local levels of the immune-suppressive mycolactone toxin, and allowing local recovery of
the host immune response to clear remaining bacteria. What is more, in vitro studies have
demonstrated the sterilizing activity of synergistic combinations of beta-lactams and rifampi-
cin [28], which could target those remaining persistent populations, thus shortening treatment
and healing times. Rapid bacterial killing would also imply a reduction in the risk of develop-
ment of resistance; even in the scenario of infections caused by bacteria resistant to rifampicin,
this could still be re-introduced for BU therapy if it was administered with amoxicillin/
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clavulanate, as previously demonstrated in M. tuberculosis [28]. Finally, because of their syner-
gistic interactions with clarithromycin, it could replace rifampicin in the treatment of HIV
patients under anti-retroviral therapy.
Our study comes as well with some limitations. First, although representative of different
geographical origins, we only tested one ATCC strain and 9 clinical isolates. Further in vitro
studies with a larger set of M. ulcerans clinical isolates would be needed to assess the full clini-
cal potential and coverage of a triple combination including rifampicin, clarithromycin and
amoxicillin/clavulanate. Second, our results were generated using synergy assays based on
MIC determinations. This implies two limitations: (i) although an established approach in
antimicrobial synergy assays, the activities of drugs alone and in combination were determined
at a single time point after seven days of drug exposure and, (ii) synergy calculations inherently
rely on sub-MIC concentrations, instead of actual serum levels achieved by drugs in clinical
therapy. In order to thoroughly assess the effect of an eventual rifampicin, clarithromycin and
amoxicillin/clavulanate combination at therapeutic concentrations, time kill assays would be
required. However, even these assays would be challenging; since serum levels would be much
higher than MIC values, the individual activity of drugs would mask any synergy signal using
bactericidal activity as endpoint readout. Under these circumstances, and the much longer
generation time of M. ulcerans compared to M. tuberculosis, assessing the sterilization capacity
of such combinations would require extensive (months) incubation times of M. ulcerans cul-
tures. Nevertheless, time kill assays are static pharmacokinetic (PK) / pharmacodynamics (PD)
models where drugs are only added at the beginning of the assays and do not reproduce clini-
cal therapy. The hollow fiber system, a dynamic PK/PD model by which posology and length
of treatment can be mimicked in vitro, might provide data with higher prediction potential of
treatment outcomes. This technology has proven a useful tool in the TB field, recently
endorsed by the European Medicines Agency [65]; however, to date no laboratory has reported
work on M. ulcerans using the hollow fiber system. Reasons for this might include the difficul-
ties of working with a BSL3 pathogen that forms colonies in 2–4 months. Finally, in the field of
BU (and TB), it is common practice to perform preclinical evaluation of drugs (or drug combi-
nations) identified by in vitro studies using murine models of M. ulcerans infection. Although
promising, experience from TB research has revealed inconsistencies between murine model
data and clinical predictability [66, 67]. In addition, mice are a sub-optimal in vivo model to
evaluate the activity of beta-lactams since their pharmacokinetics and efficacy in mice do not
predict those found in humans [68]; this is in part due to the fact that mice express an enzyme
that degrades beta lactams (renal dehydropeptidase I, DPH-I) at levels that are several orders
of magnitude higher than in humans [69, 70], thus effectively reducing the time beta-lactams
are over the MIC value. As such, murine models might not be the most appropriate develop-
ment strategy for the use of beta-lactams in BU therapy. Because amoxicillin/clavulanate is a
well-known antimicrobial with a clear track record of safety over decades of use, we believe
that direct evaluation in clinical trials would be the fastest route to improve treatment of BU
patients.
In summary, using a repurposing approach and in vitro technology already developed in
TB R&D programs, we have identified amoxicillin/clavulanate as a new potential anti-BU drug
to be used alone or in combination therapy with rifampicin and clarithromycin, current first-
line anti-BU drugs, with the potential to reduce length of therapy and time to healing. Based
on the strong synergistic interactions among amoxicillin with rifampicin and clarithromycin,
amoxicillin alone might be added to the full course of a shorter therapy. However, because the
main role of amoxicillin/clavulanate in the anti-BU therapy would be to reduce the initial bac-
terial load found in the lesions, we propose the use of high-dose extended release formulations
during the first two weeks of therapy.
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